Last updated: September 1, 2026
Fluorometholone acetate/tobramycin is a mature ophthalmic corticosteroid-antibiotic combination with limited publicly disclosed revenue, no meaningful biologic or biosimilar exposure, and low structural barriers to generic competition. Its commercial value depends on prescription volume, formulary placement, ophthalmology distribution, manufacturing reliability, and brand recognition rather than on long-dated exclusivity.
Public sources do not report standalone sales or a current product-level financial forecast for the combination. The available evidence supports a mature, price-sensitive market with limited upside and continuing erosion risk.
What is fluorometholone acetate and tobramycin used for?
Fluorometholone acetate/tobramycin combines:
- Fluorometholone acetate, a topical ophthalmic corticosteroid
- Tobramycin, an aminoglycoside antibacterial agent
The combination is used for steroid-responsive inflammatory ocular conditions in which a bacterial infection or risk of bacterial infection exists. FDA labeling for ophthalmic corticosteroid-antibiotic products restricts use to conditions where the benefits of both components are clinically justified. Prolonged use requires monitoring for increased intraocular pressure, glaucoma, delayed healing, cataract formation, and secondary infection.[1]
The product is administered topically to the eye, usually as an ophthalmic suspension. Its commercial market is narrower than the market for standalone antibiotics, standalone corticosteroids, and newer anti-inflammatory products.
How does the product compare with similar ophthalmic drugs?
| Product category |
Active ingredients |
Main commercial role |
Competitive pressure |
| Fluorometholone acetate/tobramycin |
Corticosteroid plus aminoglycoside |
Ocular inflammation with bacterial risk |
High |
| Tobramycin/dexamethasone |
Aminoglycoside plus corticosteroid |
Broadly recognized steroid-antibiotic alternative |
High |
| Tobramycin alone |
Aminoglycoside |
Bacterial eye infections |
High |
| Fluorometholone alone |
Corticosteroid |
Ocular inflammation |
High |
| Loteprednol/tobramycin |
Soft corticosteroid plus antibiotic |
Branded and generic steroid-antibiotic treatment |
Moderate to high |
| Difluprednate or loteprednol products |
Newer corticosteroid options |
Potent anti-inflammatory treatment |
Moderate |
Tobramycin/dexamethasone has greater commercial recognition and a broader generic presence. Fluorometholone acetate/tobramycin competes primarily in price-sensitive ophthalmology channels and may be substituted based on physician preference, payer policy, availability, and formulary restrictions.
What is the FDA regulatory status of fluorometholone acetate/tobramycin?
The combination is an ophthalmic prescription drug regulated through the FDA drug approval system. Product-specific status must be evaluated by National Drug Code, application number, manufacturer, and marketing status because the same active-ingredient combination can appear across multiple discontinued, abbreviated, or repackaged products.[2]
The FDA framework for this product class includes:
- New drug applications for branded or innovator products.
- Abbreviated new drug applications for therapeutically equivalent generic products.
- Manufacturing and quality requirements for sterile ophthalmic suspensions.
- Labeling restrictions related to corticosteroid use and intraocular pressure.
- Product-specific therapeutic-equivalence determinations.
A suspension product can face more development and quality-control requirements than a simple ophthalmic solution. Particle-size distribution, sedimentation, resuspendability, uniformity of dose, sterility, container closure, and preservative performance affect product quality and generic development.
What is the Orange Book status?
The FDA Orange Book is the controlling public source for listed patents, exclusivity, therapeutic equivalence, and application-level information.[3] For a mature fluorometholone acetate/tobramycin product, the key questions are:
- Whether the referenced application remains approved and marketed.
- Whether any patents are currently listed for the relevant application.
- Whether an approved generic has an A-rating.
- Whether the reference product is discontinued or still commercially available.
- Whether any listed patent has expired, been delisted, or become irrelevant to a current marketed product.
There is no commercially significant expectation of new chemical entity exclusivity for this legacy combination. Any remaining protection would more likely involve formulation, manufacturing, device, packaging, or product-specific claims rather than composition-of-matter protection for the active ingredients.
When does fluorometholone acetate/tobramycin lose exclusivity?
The active ingredients are old, off-patent molecules. The principal exclusivity periods associated with new chemical entities expired many years ago. Market access therefore depends on the status of individual applications and patents rather than a single future loss-of-exclusivity date.
What patent protection is likely to remain?
Potential patent categories include:
- Ophthalmic suspension formulations
- Particle-size and physical-stability controls
- Preservative systems
- Container-closure configurations
- Dosing or administration methods
- Manufacturing processes
- Specific combinations of concentrations or excipients
For a mature ophthalmic combination, these claims generally provide narrower protection than composition-of-matter patents. They may affect a particular generic formulation without preventing all generic entry.
No current, broadly recognized patent estate is publicly associated with a major future exclusivity event for fluorometholone acetate/tobramycin. A definitive patent determination requires matching the exact reference-listed drug and application against current Orange Book listings and USPTO records.
Are there Paragraph IV challenges to fluorometholone acetate/tobramycin?
Paragraph IV litigation is less commercially consequential for this product than for high-revenue drugs. A generic applicant can challenge listed patents by certifying that a patent is invalid, unenforceable, or will not be infringed. If the reference application has no relevant unexpired listed patents, an ANDA applicant can rely on other certification pathways.
The commercial incentives for a Paragraph IV challenge are limited because:
- The product has a small addressable market relative to major ophthalmic drugs.
- Generic entry may produce rapid price compression.
- Multiple ophthalmic steroid-antibiotic substitutes already exist.
- Manufacturing sterile ophthalmic suspensions creates quality and supply-chain risk.
- Litigation costs can exceed expected returns when annual brand sales are modest.
No major, widely reported Paragraph IV campaign or settlement agreement has established a material market barrier for this combination. Public litigation databases should be reviewed by application number and product name because cases involving the individual components or other steroid-antibiotic combinations do not necessarily apply to this product.
How many patents cover fluorometholone acetate/tobramycin?
The commercially relevant number is likely low, and no broad patent thicket is evident from the public market profile. The count should be separated into:
| Patent type |
Expected relevance |
| Composition-of-matter patents |
Effectively expired for the legacy active ingredients |
| Combination patents |
Likely expired or narrow |
| Formulation patents |
Potentially relevant to specific suspension designs |
| Manufacturing patents |
Potentially relevant to process control |
| Device and packaging patents |
Usually limited commercial scope |
| Method-of-use patents |
Possible but difficult to enforce broadly in a generic ophthalmic market |
A patent count without application-level matching can overstate protection. Family members, expired patents, continuations, and patents covering unrelated strengths should not be counted as active barriers.
What formulations are protected?
The formulation is commercially important because ophthalmic suspensions are technically more difficult to reproduce than simple solutions.
Potential formulation variables include:
- Fluorometholone acetate concentration
- Tobramycin concentration
- Suspending agents
- Surfactants and wetting agents
- Buffer system
- Preservatives
- Viscosity
- Particle-size profile
- Shake instructions
- Dropper-bottle performance
A generic applicant must demonstrate pharmaceutical equivalence and bioequivalence under the applicable FDA pathway. For topical ophthalmic products, the FDA may assess sameness of active ingredients, dosage form, route, strength, quality attributes, and product performance. Manufacturing deviations can create regulatory deficiencies even when the active ingredients are identical.
Formulation complexity creates a manufacturing barrier, but it is not equivalent to durable patent exclusivity. Once a technically acceptable generic is approved, price competition can be substantial.
What generic entry risks exist?
Generic entry risk is high. The product contains old active ingredients, is administered locally, and competes in a therapeutic category with established generic alternatives.
The most likely generic-entry scenarios are:
Immediate multi-source competition
If several approved manufacturers already supply the market, the product is exposed to ongoing reimbursement pressure, wholesaler substitution, and pharmacy-level switching.
Single-generic stabilization
A single approved supplier may preserve higher prices temporarily, particularly if manufacturing capacity is constrained. This position is vulnerable to new entrants and contract-manufacturing changes.
Supply-driven price volatility
Sterile ophthalmic products can experience shortages caused by plant inspections, contamination controls, packaging interruptions, or limited active pharmaceutical ingredient supply. Temporary shortages may increase prices without improving long-term franchise economics.
Brand persistence in selected accounts
Prescriber familiarity, local formulary preference, and perceived tolerability can preserve residual branded demand. This effect is usually insufficient to support high growth once interchangeable generics are available.
Which companies compete with fluorometholone acetate/tobramycin?
Competition comes from branded manufacturers, generic ophthalmic suppliers, and companies selling alternative steroid-antibiotic combinations.
Relevant competitive groups include:
- Bausch + Lomb and other established ophthalmic manufacturers
- Generic suppliers such as Sandoz, Akorn-related product lines, and other FDA-approved ophthalmic manufacturers
- Manufacturers of tobramycin/dexamethasone products
- Manufacturers of fluorometholone, loteprednol, dexamethasone, and other topical corticosteroids
- Contract manufacturers supplying ophthalmic suspensions and solutions
The competitive landscape is fragmented. No single company appears to control a durable, high-growth platform based solely on fluorometholone acetate/tobramycin.
What is the financial trajectory?
Standalone financial disclosure is not available for the combination in major public company filings. Companies generally report ophthalmology revenue at a portfolio or business-unit level rather than by low-revenue legacy ophthalmic product.
The likely trajectory is mature to declining:
| Financial driver |
Directional effect |
| Generic substitution |
Negative |
| Price concessions and rebates |
Negative |
| Stable chronic ophthalmology demand |
Supportive |
| Aging population and eye-care utilization |
Supportive |
| Competition from other combinations |
Negative |
| Manufacturing shortages |
Volatile |
| New patent exclusivity |
Limited |
| New clinical differentiation |
Limited |
Revenue exposure is likely modest for diversified manufacturers. The product can still contribute cash flow if manufacturing costs are low, distribution is efficient, and the company owns an established ophthalmic sales channel. Its value is more likely to arise from portfolio completeness, customer retention, and incremental margin than from independent growth.
What could improve the commercial outlook?
Upside would require one or more of the following:
- Reduced competition through supplier exits
- A differentiated preservative-free or improved-tolerability formulation
- Better formulary placement
- Reliable supply during competitor shortages
- Expansion through licensing or regional distribution
- A focused ophthalmology sales infrastructure
- Manufacturing cost advantages
Clinical differentiation would need to be demonstrated against established steroid-antibiotic alternatives. Patent protection alone would have limited value unless it covered a clinically meaningful and difficult-to-design-around formulation.
What licensing deals affect the product?
No major, publicly disclosed licensing transaction appears to define the current market for fluorometholone acetate/tobramycin. Legacy ophthalmic products may have changed ownership through asset purchases, product-line transfers, co-promotion arrangements, or manufacturing agreements that are not disclosed as standalone transactions.
Licensing value would depend on:
- Rights by country or region
- Existing approvals
- Manufacturing transfer requirements
- Product availability
- Patent and trademark status
- Gross-to-net pricing
- Distribution economics
- Pharmacovigilance obligations
For a mature generic or legacy branded product, an acquisition is more likely to be structured around a broader ophthalmology portfolio than around this combination alone.
What is the geographic market coverage?
The United States is the most transparent market because FDA application, Orange Book, label, and litigation data are publicly accessible. International availability is less standardized.
Market coverage may vary by:
- National approval status
- Local brand ownership
- Prescription classification
- Generic substitution rules
- Reimbursement policy
- Patent and regulatory linkage
- Sterile manufacturing capacity
- Distributor relationships
A product approved in the United States does not imply approval or active marketing in Europe, Canada, Japan, Latin America, or emerging markets. International revenue should not be inferred from U.S. approval status.
How strong is the patent estate?
The patent estate is weak from an exclusivity perspective and moderate from a manufacturing perspective.
- Composition protection: weak or expired.
- Regulatory exclusivity: expired for a legacy combination.
- Formulation protection: potentially narrow.
- Method-of-use protection: limited practical enforcement value.
- Manufacturing barriers: meaningful but operational rather than proprietary.
- Biosimilar protection: not applicable.
- Generic substitution risk: high.
The main defensibility is execution. Quality systems, sterile manufacturing, supply continuity, ophthalmic distribution, and payer access are more important than a broad patent moat.
Key Takeaways
- Fluorometholone acetate/tobramycin is a mature ophthalmic steroid-antibiotic combination.
- The active ingredients have long histories of use and do not support meaningful new-chemical-entity exclusivity.
- Generic substitution and alternative steroid-antibiotic products create high competitive pressure.
- Formulation and sterile-manufacturing requirements can delay entry but do not create a broad commercial moat.
- No major current Paragraph IV campaign, settlement, or patent event is publicly associated with the combination.
- Standalone product revenue is not disclosed by major manufacturers.
- The financial trajectory is likely stable to declining, with limited growth absent supply disruption, formulation differentiation, or portfolio-level strategic value.
- Biosimilar risk is not relevant because the product is a small-molecule ophthalmic drug, not a biologic.
- The most important diligence items are current FDA marketing status, Orange Book application data, approved generic suppliers, product availability, and manufacturer-level ophthalmology revenue.
FAQs
Is fluorometholone acetate/tobramycin the same as Tobradex?
No. Tobradex contains tobramycin and dexamethasone. Fluorometholone acetate/tobramycin uses fluorometholone acetate as the corticosteroid. The products are therapeutic alternatives in some settings but are not compositionally identical.
Does fluorometholone acetate/tobramycin have biosimilars?
No. Biosimilars apply to biologic products. Fluorometholone acetate/tobramycin is a small-molecule ophthalmic drug and is subject to generic-drug, not biosimilar, competition.
Can a generic manufacturer avoid a formulation patent?
A generic applicant may use a non-infringing formulation or challenge a listed patent through the applicable FDA certification pathway. The commercial outcome depends on the exact patent claims, Orange Book listing, application, and product design.
Is the product exposed to ophthalmic drug shortages?
Potentially. Sterile ophthalmic products can face supply interruptions from manufacturing inspections, contamination events, packaging constraints, or limited production capacity. A shortage can temporarily improve pricing but generally does not change the long-term mature-market profile.
Is fluorometholone acetate/tobramycin attractive for licensing?
It may be commercially relevant as part of a broader ophthalmology portfolio, particularly where a buyer has low-cost sterile manufacturing and established distribution. As a standalone licensing asset, its value is constrained by generic competition, limited differentiation, and the absence of visible long-term exclusivity.
References
-
U.S. Food and Drug Administration. (n.d.). Ophthalmic corticosteroid and antibiotic product labeling. FDA Drugs@FDA and prescribing information database.
-
U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/
-
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
-
U.S. Food and Drug Administration. (n.d.). Abbreviated new drug application process for generic drugs. https://www.fda.gov/drugs/abbreviated-new-drug-application-anda
-
U.S. Patent and Trademark Office. (n.d.). Patent Center. https://patentcenter.uspto.gov/
